Medicines targeting the renin-angiotensin-aldosterone program (RAAS) will be the mainstay of therapy to retard the development of proteinuric chronic kidney disease (CKD) such as for example diabetic nephropathy. end-stage renal disease (ESRD) [2]. The renin-angiotensin-aldosterone program (RAAS) is a significant pathway mixed up in pathogenesis and development of DN [3, 4], and RAAS blockade is… Continue reading Medicines targeting the renin-angiotensin-aldosterone program (RAAS) will be the mainstay of